Global Tuberculosis Vaccines Market

Tuberculosis Vaccines Comprehensive Study by Type (Immunotherapeutic Vaccines, Booster Vaccines, Others), Application (Hospitals, Clinics, Others), Testing Type (Tuberculin Skin Test (TST), TB Blood Tests) Players and Region - Global Market Outlook to 2026

Tuberculosis Vaccines Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Tuberculosis Vaccines?
Tuberculosis (TB) is a major and deadly disease caused by the tuberculosis bacteria, Mycobacterium Tuberculosis (Mtb). Bacille Calmette-Guérin (BCG) is the vaccine for TB. This vaccine is not widely used in the United States, but it is often given to infants and small children in other countries where TB is common. BCG does not always protect people from getting TB, however, it prevents some serious TB complications in children. TB is considered a poverty-related disease affecting the poorest countries. Apart from human suffering, TB causes an economic burden. According to the World Health Organisation (WHO), it is estimated that about a third of the world’s population is infected with Mtb. In 2017, 10 million people fell ill with TB and 1.6 million of these people died. The BCG vaccine reaches more than 80% of all newborn children and infants in countries where it is part of the national childhood immunization program.

The market study is broken down by Type (Immunotherapeutic Vaccines, Booster Vaccines and Others), by Application (Hospitals, Clinics and Others) and major geographies with country level break-up.

Analysts at AMA Research estimates that Players from Indians will contribute to the maximum growth of Global Tuberculosis Vaccines market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Sanofi (France), Merck & Co. (United States), GreenSignal Bio Pharma (India), GlaxoSmithKline (United Kingdom), Japan BCG Laboratory (Japan), IDT Biologika (Germany), Taj Pharmaceuticals (India), AJ Pharma Holding (Malaysia), Serum Institute of India (India) and Statens Serum Institute (Denmark) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Intervax Ltd. (Canada).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Tuberculosis Vaccines market by Type, Application and Region.

On the basis of geography, the market of Tuberculosis Vaccines has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Testing Type, the sub-segment i.e. Tuberculin Skin Test (TST) will boost the Tuberculosis Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.


The general manufacturing recommendations for manufacturing establishments are contained in WHO’s Good manufacturing practices. BCG is susceptible to sunlight. Therefore, the procedures for the preparation of the vaccine should be so designed that all cultures and vaccines are protected from direct sunlight and ultraviolet light at all stages of manufacture, testing, and storage until the vaccine is issued. The production culture medium should contain no substances known to cause toxic or allergic reactions in humans. The label, and/or the packaging insert in some countries, printed on or affixed to each container should show the volume and nature of the diluent.

Market Trend
  • Highest Demand from Developing & Underdeveloped Nations

Market Drivers
  • Government Initiatives to Eradicate Tuberculosis

Opportunities
  • Breakthrough Innovations to Improve the Efficacy of Vaccines

Restraints
  • Regulations to Ensure Quality, Efficacy & Safety of Vaccines

Challenges
  • Increased Investment Requirements for Mid & Late-Stage R&D & Manufacturing


Key Target Audience
Tuberculosis Vaccine Manufacturer, Distributor & Supplier, Healthcare Industry, Government Bodies & Associations, Raw Material Supplier, End-User and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Type
  • Immunotherapeutic Vaccines
  • Booster Vaccines
  • Others
By Application
  • Hospitals
  • Clinics
  • Others
By Testing Type
  • Tuberculin Skin Test (TST)
  • TB Blood Tests

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Government Initiatives to Eradicate Tuberculosis
    • 3.3. Market Challenges
      • 3.3.1. Increased Investment Requirements for Mid & Late-Stage R&D & Manufacturing
    • 3.4. Market Trends
      • 3.4.1. Highest Demand from Developing & Underdeveloped Nations
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Tuberculosis Vaccines, by Type, Application, Testing Type and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Tuberculosis Vaccines (Value)
      • 5.2.1. Global Tuberculosis Vaccines by: Type (Value)
        • 5.2.1.1. Immunotherapeutic Vaccines
        • 5.2.1.2. Booster Vaccines
        • 5.2.1.3. Others
      • 5.2.2. Global Tuberculosis Vaccines by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Tuberculosis Vaccines by: Testing Type (Value)
        • 5.2.3.1. Tuberculin Skin Test (TST)
        • 5.2.3.2. TB Blood Tests
      • 5.2.4. Global Tuberculosis Vaccines Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Tuberculosis Vaccines (Volume)
      • 5.3.1. Global Tuberculosis Vaccines by: Type (Volume)
        • 5.3.1.1. Immunotherapeutic Vaccines
        • 5.3.1.2. Booster Vaccines
        • 5.3.1.3. Others
      • 5.3.2. Global Tuberculosis Vaccines by: Application (Volume)
        • 5.3.2.1. Hospitals
        • 5.3.2.2. Clinics
        • 5.3.2.3. Others
      • 5.3.3. Global Tuberculosis Vaccines by: Testing Type (Volume)
        • 5.3.3.1. Tuberculin Skin Test (TST)
        • 5.3.3.2. TB Blood Tests
      • 5.3.4. Global Tuberculosis Vaccines Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Tuberculosis Vaccines (Price)
      • 5.4.1. Global Tuberculosis Vaccines by: Type (Price)
  • 6. Tuberculosis Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck & Co. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GreenSignal Bio Pharma (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Japan BCG Laboratory (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. IDT Biologika (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Taj Pharmaceuticals (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AJ Pharma Holding (Malaysia)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Serum Institute of India (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Statens Serum Institute (Denmark)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Tuberculosis Vaccines Sale, by Type, Application, Testing Type and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Tuberculosis Vaccines (Value)
      • 7.2.1. Global Tuberculosis Vaccines by: Type (Value)
        • 7.2.1.1. Immunotherapeutic Vaccines
        • 7.2.1.2. Booster Vaccines
        • 7.2.1.3. Others
      • 7.2.2. Global Tuberculosis Vaccines by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Tuberculosis Vaccines by: Testing Type (Value)
        • 7.2.3.1. Tuberculin Skin Test (TST)
        • 7.2.3.2. TB Blood Tests
      • 7.2.4. Global Tuberculosis Vaccines Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Tuberculosis Vaccines (Volume)
      • 7.3.1. Global Tuberculosis Vaccines by: Type (Volume)
        • 7.3.1.1. Immunotherapeutic Vaccines
        • 7.3.1.2. Booster Vaccines
        • 7.3.1.3. Others
      • 7.3.2. Global Tuberculosis Vaccines by: Application (Volume)
        • 7.3.2.1. Hospitals
        • 7.3.2.2. Clinics
        • 7.3.2.3. Others
      • 7.3.3. Global Tuberculosis Vaccines by: Testing Type (Volume)
        • 7.3.3.1. Tuberculin Skin Test (TST)
        • 7.3.3.2. TB Blood Tests
      • 7.3.4. Global Tuberculosis Vaccines Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Tuberculosis Vaccines (Price)
      • 7.4.1. Global Tuberculosis Vaccines by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Tuberculosis Vaccines: by Type(USD Million)
  • Table 2. Tuberculosis Vaccines Immunotherapeutic Vaccines , by Region USD Million (2015-2020)
  • Table 3. Tuberculosis Vaccines Booster Vaccines , by Region USD Million (2015-2020)
  • Table 4. Tuberculosis Vaccines Others , by Region USD Million (2015-2020)
  • Table 5. Tuberculosis Vaccines: by Application(USD Million)
  • Table 6. Tuberculosis Vaccines Hospitals , by Region USD Million (2015-2020)
  • Table 7. Tuberculosis Vaccines Clinics , by Region USD Million (2015-2020)
  • Table 8. Tuberculosis Vaccines Others , by Region USD Million (2015-2020)
  • Table 9. Tuberculosis Vaccines: by Testing Type(USD Million)
  • Table 10. Tuberculosis Vaccines Tuberculin Skin Test (TST) , by Region USD Million (2015-2020)
  • Table 11. Tuberculosis Vaccines TB Blood Tests , by Region USD Million (2015-2020)
  • Table 12. South America Tuberculosis Vaccines, by Country USD Million (2015-2020)
  • Table 13. South America Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 14. South America Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 15. South America Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 16. Brazil Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 17. Brazil Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 18. Brazil Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 19. Argentina Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 20. Argentina Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 21. Argentina Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 22. Rest of South America Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 23. Rest of South America Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 24. Rest of South America Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 25. Asia Pacific Tuberculosis Vaccines, by Country USD Million (2015-2020)
  • Table 26. Asia Pacific Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 27. Asia Pacific Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 28. Asia Pacific Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 29. China Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 30. China Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 31. China Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 32. Japan Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 33. Japan Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 34. Japan Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 35. India Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 36. India Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 37. India Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 38. South Korea Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 39. South Korea Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 40. South Korea Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 41. Taiwan Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 42. Taiwan Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 43. Taiwan Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 44. Australia Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 45. Australia Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 46. Australia Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 50. Europe Tuberculosis Vaccines, by Country USD Million (2015-2020)
  • Table 51. Europe Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 52. Europe Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 53. Europe Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 54. Germany Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 55. Germany Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 56. Germany Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 57. France Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 58. France Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 59. France Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 60. Italy Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 61. Italy Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 62. Italy Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 63. United Kingdom Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 64. United Kingdom Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 65. United Kingdom Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 66. Netherlands Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 67. Netherlands Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 68. Netherlands Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 69. Rest of Europe Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 70. Rest of Europe Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 71. Rest of Europe Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 72. MEA Tuberculosis Vaccines, by Country USD Million (2015-2020)
  • Table 73. MEA Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 74. MEA Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 75. MEA Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 76. Middle East Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 77. Middle East Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 78. Middle East Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 79. Africa Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 80. Africa Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 81. Africa Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 82. North America Tuberculosis Vaccines, by Country USD Million (2015-2020)
  • Table 83. North America Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 84. North America Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 85. North America Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 86. United States Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 87. United States Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 88. United States Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 89. Canada Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 90. Canada Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 91. Canada Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 92. Mexico Tuberculosis Vaccines, by Type USD Million (2015-2020)
  • Table 93. Mexico Tuberculosis Vaccines, by Application USD Million (2015-2020)
  • Table 94. Mexico Tuberculosis Vaccines, by Testing Type USD Million (2015-2020)
  • Table 95. Tuberculosis Vaccines Sales: by Type(K Units)
  • Table 96. Tuberculosis Vaccines Sales Immunotherapeutic Vaccines , by Region K Units (2015-2020)
  • Table 97. Tuberculosis Vaccines Sales Booster Vaccines , by Region K Units (2015-2020)
  • Table 98. Tuberculosis Vaccines Sales Others , by Region K Units (2015-2020)
  • Table 99. Tuberculosis Vaccines Sales: by Application(K Units)
  • Table 100. Tuberculosis Vaccines Sales Hospitals , by Region K Units (2015-2020)
  • Table 101. Tuberculosis Vaccines Sales Clinics , by Region K Units (2015-2020)
  • Table 102. Tuberculosis Vaccines Sales Others , by Region K Units (2015-2020)
  • Table 103. Tuberculosis Vaccines Sales: by Testing Type(K Units)
  • Table 104. Tuberculosis Vaccines Sales Tuberculin Skin Test (TST) , by Region K Units (2015-2020)
  • Table 105. Tuberculosis Vaccines Sales TB Blood Tests , by Region K Units (2015-2020)
  • Table 106. South America Tuberculosis Vaccines Sales, by Country K Units (2015-2020)
  • Table 107. South America Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 108. South America Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 109. South America Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 110. Brazil Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 111. Brazil Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 112. Brazil Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 113. Argentina Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 114. Argentina Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 115. Argentina Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 116. Rest of South America Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 117. Rest of South America Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 118. Rest of South America Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 119. Asia Pacific Tuberculosis Vaccines Sales, by Country K Units (2015-2020)
  • Table 120. Asia Pacific Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 121. Asia Pacific Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 122. Asia Pacific Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 123. China Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 124. China Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 125. China Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 126. Japan Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 127. Japan Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 128. Japan Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 129. India Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 130. India Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 131. India Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 132. South Korea Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 133. South Korea Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 134. South Korea Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 135. Taiwan Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 136. Taiwan Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 137. Taiwan Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 138. Australia Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 139. Australia Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 140. Australia Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 141. Rest of Asia-Pacific Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 142. Rest of Asia-Pacific Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 143. Rest of Asia-Pacific Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 144. Europe Tuberculosis Vaccines Sales, by Country K Units (2015-2020)
  • Table 145. Europe Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 146. Europe Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 147. Europe Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 148. Germany Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 149. Germany Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 150. Germany Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 151. France Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 152. France Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 153. France Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 154. Italy Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 155. Italy Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 156. Italy Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 157. United Kingdom Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 158. United Kingdom Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 159. United Kingdom Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 160. Netherlands Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 161. Netherlands Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 162. Netherlands Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 163. Rest of Europe Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 164. Rest of Europe Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 165. Rest of Europe Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 166. MEA Tuberculosis Vaccines Sales, by Country K Units (2015-2020)
  • Table 167. MEA Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 168. MEA Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 169. MEA Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 170. Middle East Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 171. Middle East Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 172. Middle East Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 173. Africa Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 174. Africa Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 175. Africa Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 176. North America Tuberculosis Vaccines Sales, by Country K Units (2015-2020)
  • Table 177. North America Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 178. North America Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 179. North America Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 180. United States Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 181. United States Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 182. United States Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 183. Canada Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 184. Canada Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 185. Canada Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 186. Mexico Tuberculosis Vaccines Sales, by Type K Units (2015-2020)
  • Table 187. Mexico Tuberculosis Vaccines Sales, by Application K Units (2015-2020)
  • Table 188. Mexico Tuberculosis Vaccines Sales, by Testing Type K Units (2015-2020)
  • Table 189. Tuberculosis Vaccines: by Type(USD/Units)
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Tuberculosis Vaccines: by Type(USD Million)
  • Table 201. Tuberculosis Vaccines Immunotherapeutic Vaccines , by Region USD Million (2021-2026)
  • Table 202. Tuberculosis Vaccines Booster Vaccines , by Region USD Million (2021-2026)
  • Table 203. Tuberculosis Vaccines Others , by Region USD Million (2021-2026)
  • Table 204. Tuberculosis Vaccines: by Application(USD Million)
  • Table 205. Tuberculosis Vaccines Hospitals , by Region USD Million (2021-2026)
  • Table 206. Tuberculosis Vaccines Clinics , by Region USD Million (2021-2026)
  • Table 207. Tuberculosis Vaccines Others , by Region USD Million (2021-2026)
  • Table 208. Tuberculosis Vaccines: by Testing Type(USD Million)
  • Table 209. Tuberculosis Vaccines Tuberculin Skin Test (TST) , by Region USD Million (2021-2026)
  • Table 210. Tuberculosis Vaccines TB Blood Tests , by Region USD Million (2021-2026)
  • Table 211. South America Tuberculosis Vaccines, by Country USD Million (2021-2026)
  • Table 212. South America Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 213. South America Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 214. South America Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 215. Brazil Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 216. Brazil Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 217. Brazil Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 218. Argentina Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 219. Argentina Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 220. Argentina Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 221. Rest of South America Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 222. Rest of South America Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 223. Rest of South America Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 224. Asia Pacific Tuberculosis Vaccines, by Country USD Million (2021-2026)
  • Table 225. Asia Pacific Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 226. Asia Pacific Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 227. Asia Pacific Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 228. China Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 229. China Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 230. China Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 231. Japan Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 232. Japan Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 233. Japan Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 234. India Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 235. India Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 236. India Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 237. South Korea Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 238. South Korea Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 239. South Korea Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 240. Taiwan Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 241. Taiwan Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 242. Taiwan Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 243. Australia Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 244. Australia Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 245. Australia Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 246. Rest of Asia-Pacific Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 247. Rest of Asia-Pacific Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 248. Rest of Asia-Pacific Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 249. Europe Tuberculosis Vaccines, by Country USD Million (2021-2026)
  • Table 250. Europe Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 251. Europe Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 252. Europe Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 253. Germany Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 254. Germany Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 255. Germany Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 256. France Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 257. France Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 258. France Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 259. Italy Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 260. Italy Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 261. Italy Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 262. United Kingdom Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 263. United Kingdom Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 264. United Kingdom Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 265. Netherlands Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 266. Netherlands Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 267. Netherlands Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 268. Rest of Europe Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 269. Rest of Europe Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 270. Rest of Europe Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 271. MEA Tuberculosis Vaccines, by Country USD Million (2021-2026)
  • Table 272. MEA Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 273. MEA Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 274. MEA Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 275. Middle East Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 276. Middle East Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 277. Middle East Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 278. Africa Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 279. Africa Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 280. Africa Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 281. North America Tuberculosis Vaccines, by Country USD Million (2021-2026)
  • Table 282. North America Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 283. North America Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 284. North America Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 285. United States Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 286. United States Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 287. United States Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 288. Canada Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 289. Canada Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 290. Canada Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 291. Mexico Tuberculosis Vaccines, by Type USD Million (2021-2026)
  • Table 292. Mexico Tuberculosis Vaccines, by Application USD Million (2021-2026)
  • Table 293. Mexico Tuberculosis Vaccines, by Testing Type USD Million (2021-2026)
  • Table 294. Tuberculosis Vaccines Sales: by Type(K Units)
  • Table 295. Tuberculosis Vaccines Sales Immunotherapeutic Vaccines , by Region K Units (2021-2026)
  • Table 296. Tuberculosis Vaccines Sales Booster Vaccines , by Region K Units (2021-2026)
  • Table 297. Tuberculosis Vaccines Sales Others , by Region K Units (2021-2026)
  • Table 298. Tuberculosis Vaccines Sales: by Application(K Units)
  • Table 299. Tuberculosis Vaccines Sales Hospitals , by Region K Units (2021-2026)
  • Table 300. Tuberculosis Vaccines Sales Clinics , by Region K Units (2021-2026)
  • Table 301. Tuberculosis Vaccines Sales Others , by Region K Units (2021-2026)
  • Table 302. Tuberculosis Vaccines Sales: by Testing Type(K Units)
  • Table 303. Tuberculosis Vaccines Sales Tuberculin Skin Test (TST) , by Region K Units (2021-2026)
  • Table 304. Tuberculosis Vaccines Sales TB Blood Tests , by Region K Units (2021-2026)
  • Table 305. South America Tuberculosis Vaccines Sales, by Country K Units (2021-2026)
  • Table 306. South America Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 307. South America Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 308. South America Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 309. Brazil Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 310. Brazil Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 311. Brazil Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 312. Argentina Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 313. Argentina Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 314. Argentina Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 315. Rest of South America Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 316. Rest of South America Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 317. Rest of South America Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 318. Asia Pacific Tuberculosis Vaccines Sales, by Country K Units (2021-2026)
  • Table 319. Asia Pacific Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 320. Asia Pacific Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 321. Asia Pacific Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 322. China Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 323. China Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 324. China Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 325. Japan Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 326. Japan Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 327. Japan Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 328. India Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 329. India Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 330. India Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 331. South Korea Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 332. South Korea Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 333. South Korea Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 334. Taiwan Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 335. Taiwan Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 336. Taiwan Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 337. Australia Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 338. Australia Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 339. Australia Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 340. Rest of Asia-Pacific Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 341. Rest of Asia-Pacific Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 342. Rest of Asia-Pacific Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 343. Europe Tuberculosis Vaccines Sales, by Country K Units (2021-2026)
  • Table 344. Europe Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 345. Europe Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 346. Europe Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 347. Germany Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 348. Germany Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 349. Germany Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 350. France Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 351. France Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 352. France Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 353. Italy Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 354. Italy Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 355. Italy Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 356. United Kingdom Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 357. United Kingdom Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 358. United Kingdom Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 359. Netherlands Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 360. Netherlands Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 361. Netherlands Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 362. Rest of Europe Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 363. Rest of Europe Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 364. Rest of Europe Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 365. MEA Tuberculosis Vaccines Sales, by Country K Units (2021-2026)
  • Table 366. MEA Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 367. MEA Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 368. MEA Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 369. Middle East Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 370. Middle East Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 371. Middle East Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 372. Africa Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 373. Africa Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 374. Africa Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 375. North America Tuberculosis Vaccines Sales, by Country K Units (2021-2026)
  • Table 376. North America Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 377. North America Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 378. North America Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 379. United States Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 380. United States Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 381. United States Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 382. Canada Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 383. Canada Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 384. Canada Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 385. Mexico Tuberculosis Vaccines Sales, by Type K Units (2021-2026)
  • Table 386. Mexico Tuberculosis Vaccines Sales, by Application K Units (2021-2026)
  • Table 387. Mexico Tuberculosis Vaccines Sales, by Testing Type K Units (2021-2026)
  • Table 388. Tuberculosis Vaccines: by Type(USD/Units)
  • Table 389. Research Programs/Design for This Report
  • Table 390. Key Data Information from Secondary Sources
  • Table 391. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Tuberculosis Vaccines: by Type USD Million (2015-2020)
  • Figure 5. Global Tuberculosis Vaccines: by Application USD Million (2015-2020)
  • Figure 6. Global Tuberculosis Vaccines: by Testing Type USD Million (2015-2020)
  • Figure 7. South America Tuberculosis Vaccines Share (%), by Country
  • Figure 8. Asia Pacific Tuberculosis Vaccines Share (%), by Country
  • Figure 9. Europe Tuberculosis Vaccines Share (%), by Country
  • Figure 10. MEA Tuberculosis Vaccines Share (%), by Country
  • Figure 11. North America Tuberculosis Vaccines Share (%), by Country
  • Figure 12. Global Tuberculosis Vaccines: by Type K Units (2015-2020)
  • Figure 13. Global Tuberculosis Vaccines: by Application K Units (2015-2020)
  • Figure 14. Global Tuberculosis Vaccines: by Testing Type K Units (2015-2020)
  • Figure 15. South America Tuberculosis Vaccines Share (%), by Country
  • Figure 16. Asia Pacific Tuberculosis Vaccines Share (%), by Country
  • Figure 17. Europe Tuberculosis Vaccines Share (%), by Country
  • Figure 18. MEA Tuberculosis Vaccines Share (%), by Country
  • Figure 19. North America Tuberculosis Vaccines Share (%), by Country
  • Figure 20. Global Tuberculosis Vaccines: by Type USD/Units (2015-2020)
  • Figure 21. Global Tuberculosis Vaccines share by Players 2020 (%)
  • Figure 22. Global Tuberculosis Vaccines share by Players (Top 3) 2020(%)
  • Figure 23. Global Tuberculosis Vaccines share by Players (Top 5) 2020(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 26. Sanofi (France) Revenue: by Geography 2020
  • Figure 27. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Merck & Co. (United States) Revenue: by Geography 2020
  • Figure 29. GreenSignal Bio Pharma (India) Revenue, Net Income and Gross profit
  • Figure 30. GreenSignal Bio Pharma (India) Revenue: by Geography 2020
  • Figure 31. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 33. Japan BCG Laboratory (Japan) Revenue, Net Income and Gross profit
  • Figure 34. Japan BCG Laboratory (Japan) Revenue: by Geography 2020
  • Figure 35. IDT Biologika (Germany) Revenue, Net Income and Gross profit
  • Figure 36. IDT Biologika (Germany) Revenue: by Geography 2020
  • Figure 37. Taj Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 38. Taj Pharmaceuticals (India) Revenue: by Geography 2020
  • Figure 39. AJ Pharma Holding (Malaysia) Revenue, Net Income and Gross profit
  • Figure 40. AJ Pharma Holding (Malaysia) Revenue: by Geography 2020
  • Figure 41. Serum Institute of India (India) Revenue, Net Income and Gross profit
  • Figure 42. Serum Institute of India (India) Revenue: by Geography 2020
  • Figure 43. Statens Serum Institute (Denmark) Revenue, Net Income and Gross profit
  • Figure 44. Statens Serum Institute (Denmark) Revenue: by Geography 2020
  • Figure 45. Global Tuberculosis Vaccines: by Type USD Million (2021-2026)
  • Figure 46. Global Tuberculosis Vaccines: by Application USD Million (2021-2026)
  • Figure 47. Global Tuberculosis Vaccines: by Testing Type USD Million (2021-2026)
  • Figure 48. South America Tuberculosis Vaccines Share (%), by Country
  • Figure 49. Asia Pacific Tuberculosis Vaccines Share (%), by Country
  • Figure 50. Europe Tuberculosis Vaccines Share (%), by Country
  • Figure 51. MEA Tuberculosis Vaccines Share (%), by Country
  • Figure 52. North America Tuberculosis Vaccines Share (%), by Country
  • Figure 53. Global Tuberculosis Vaccines: by Type K Units (2021-2026)
  • Figure 54. Global Tuberculosis Vaccines: by Application K Units (2021-2026)
  • Figure 55. Global Tuberculosis Vaccines: by Testing Type K Units (2021-2026)
  • Figure 56. South America Tuberculosis Vaccines Share (%), by Country
  • Figure 57. Asia Pacific Tuberculosis Vaccines Share (%), by Country
  • Figure 58. Europe Tuberculosis Vaccines Share (%), by Country
  • Figure 59. MEA Tuberculosis Vaccines Share (%), by Country
  • Figure 60. North America Tuberculosis Vaccines Share (%), by Country
  • Figure 61. Global Tuberculosis Vaccines: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Sanofi (France)
  • Merck & Co. (United States)
  • GreenSignal Bio Pharma (India)
  • GlaxoSmithKline (United Kingdom)
  • Japan BCG Laboratory (Japan)
  • IDT Biologika (Germany)
  • Taj Pharmaceuticals (India)
  • AJ Pharma Holding (Malaysia)
  • Serum Institute of India (India)
  • Statens Serum Institute (Denmark)
Additional players considered in the study are as follows:
Intervax Ltd. (Canada)
Select User Access Type

Key Highlights of Report


Dec 2021 224 Pages 79 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Tuberculosis Vaccines Market Quantitative research analysis
Global Tuberculosis Vaccines Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Sanofi (France), Merck & Co. (United States), GreenSignal Bio Pharma (India), GlaxoSmithKline (United Kingdom), Japan BCG Laboratory (Japan), IDT Biologika (Germany), Taj Pharmaceuticals (India), AJ Pharma Holding (Malaysia), Serum Institute of India (India) and Statens Serum Institute (Denmark) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
Analysts at AMA estimates Tuberculosis Vaccines Market to reach USD Million by 2026.

Know More About Global Tuberculosis Vaccines Market Report?

Have a Query? Click Here

Other Related Reports

Sulbactam Pivoxil Comprehensive Study by Application (Pharmaceutical, Research, Biosciences, Others), Form (Tablets, Powder, Suspension), Distribution Channel (Hospitals Pharmacies, Medical Stores, O...
$ 3450
Benzocaine Drugs Comprehensive Study by Type (Gel, Aerosol, Paste, Cream), Application (Dental Clinics, Hospital, Pharmacy/Drugstore), Indication (Skin Irritation, Wounds, Ulcers, Hemorrhoids, Others...
$ 3450
Ofloxacin Comprehensive Study by Type (Oral, Intravenous Therapy (IV), Topical (Eye Drops & Ear Drops)), Application (Bronchitis, Pneumonia and Infections of the Skin, Reproductive Organs, Bladder, U...
$ 3750
Dental Anesthesia Comprehensive Study by Type (Local Anesthesia, General Anesthesia), Application (Hospital, Clinic, Other), Drugs (Lidocaine, Mepivacaine, Prilocaine, Bupivacaine), Mode Of Administr...
$ 3350
Cannabidiol (CBD) Comprehensive Study by Type (Recreational, Medicinal, Synthetic.), Application (CBD For Food & beverage, CBD Cosmetics & personal Care, CBD Pharmaceutical, Other), Variants (Genus, ...
$ 3800
Dalbavancin Comprehensive Study by Type (Intravenous Therapy, Oral Type), Application (Skin Infection, Soft Tissue Infection, Others), End Users (Hospitals and clinics, Chemical firms, API demanding ...
$ 3650